Research Topics
Species | Gerrit DraismaSummaryAffiliation: Erasmus MC Country: The Netherlands Publications
| Collaborators
|
Detail Information
Publications
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate CancerGerrit Draisma
Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
J Natl Cancer Inst 95:868-78. 2003..Both consequences have considerable impact on the net benefits of screening...- MISCAN: estimating lead-time and over-detection by simulationG Draisma
Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, The Netherlands
BJU Int 92:106-11. 2003..To estimate the mean lead-time and rate of over-detection associated with screening for prostate cancer with prostate-specific antigen... 
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and contextGerrit Draisma
Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
J Natl Cancer Inst 101:374-83. 2009..Reported overdiagnosis estimates have also been variable, ranging from 25% to greater than 80% of screen-detected cancers...
Digital mammography screening: weighing reduced mortality against increased overdiagnosisRianne De Gelder
Erasmus MC, Department of Public Health, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
Prev Med 53:134-40. 2011..Digital mammography has been shown to increase the detection of ductal carcinoma in situ (DCIS) compared to screen-film mammography. The benefits and risks of such an increase were assessed...- Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-RotterdamElisabeth M Wever
Department of Public Health, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
J Natl Cancer Inst 102:352-5. 2010..26 in the United States vs 0.94 in ERSPC-Rotterdam. We conclude that the efficacy of PSA screening in detecting prostate cancer was lower in the United States than in ERSPC-Rotterdam... - Interpreting overdiagnosis estimates in population-based mammography screeningRianne De Gelder
Department of Public Health, Erasmus MC, Room AE 137, P O Box 2040, 3000 CA Rotterdam, The Netherlands
Epidemiol Rev 33:111-21. 2011..Calculations based on earlier screening program phases may overestimate overdiagnosis by a factor 4. Sufficient follow-up and agreement regarding the chosen estimator are needed to obtain reliable estimates... - Cost-effectiveness of opportunistic versus organised mammography screening in SwitzerlandRianne De Gelder
Erasmus MC, Department of Public Health, Rotterdam, The Netherlands
Eur J Cancer 45:127-38. 2009..In this study, we compared the cost-effectiveness of both screening modalities in Switzerland... - Breast cancer screening policies in developing countries: a cost-effectiveness analysis for IndiaQuirine Lamberts Okonkwo
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
J Natl Cancer Inst 100:1290-300. 2008..Estimates and comparisons of the cost-effectiveness of feasible breast cancer screening policies in developing countries and identification of the determinants of cost and efficacy are needed... - Overdiagnosis and overtreatment of breast cancer: microsimulation modelling estimates based on observed screen and clinical dataHarry J de Koning
Erasmus MC, Department of Public Health, PO Box 1738, 3000 DR Rotterdam, The Netherlands
Breast Cancer Res 8:202. 2006..The increases in ductal carcinoma in situ (DCIS) are primarily due to mammography screening, but DCIS still remains a relatively small proportion of the total breast cancer problem... - How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screeningElisabeth M Wever
Department of Public Health, Erasmus MC Rotterdam, The Netherlands
Med Decis Making 31:550-8. 2011..Two commonly used screening-effect models are the stage-shift model, where mortality benefits are explained by the shift to more favorable stages, and the cure model, where early detection enhances the chances of cure from disease... - Seventy-five years is an appropriate upper age limit for population-based mammography screeningJacques Fracheboud
Department of Public Health, NETB, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Int J Cancer 118:2020-5. 2006..At present, 75 years of age can be regarded as an appropriate upper age limit for the Dutch programme... - Breast cancer screening: evidence for false reassurance?Rianne De Gelder
Department of Public Health, Erasmus MC, 3000 CA Rotterdam, The Netherlands
Int J Cancer 123:680-6. 2008..0 days (95% C.I. 5.9-8.1) in symptomatic screened patients and 6.0 days (95% C.I. 4.0-8.0) in control patients. Our results show that false reassurance played, at most, only a minor role in breast cancer screening... - Gleason score, age and screening: modeling dedifferentiation in prostate cancerGerrit Draisma
Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
Int J Cancer 119:2366-71. 2006..Tumors dedifferentiate during the screen-detectable phase and consequently screening with PSA and early treatment can possibly prevent dedifferentiation... - Quality-of-life effects of prostate-specific antigen screeningEveline A M Heijnsdijk
Department of Public Health, Erasmus Medical Center, P O Box 2040, 3000 CA Rotterdam, The Netherlands
N Engl J Med 367:595-605. 2012..However, the extent to which harms to quality of life resulting from overdiagnosis and treatment counterbalance this benefit is uncertain... - Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United StatesNicolien T Van Ravesteyn
Department of Public Health, Erasmus MC Room AE 134, P O Box 2040, 3000 CA Rotterdam, The Netherlands
Cancer Epidemiol Biomarkers Prev 20:112-22. 2011..The aim of this study is to investigate how much of the mortality disparity can be attributed to racial differences in natural history, uptake of mammography screening, and use of adjuvant therapy... - Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON)Carola A Van Iersel
Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
Int J Cancer 120:868-74. 2007..When pooling with Danish trial data (n = +/-4,000) NELSON is the only trial without screening in controls that is expected to have 80% power to show a lung cancer mortality reduction of at least 25% 10 years after randomisation... - Mammography benefit in the Canadian National Breast Screening Study-2: a model evaluationAdriana J Rijnsburger
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Int J Cancer 110:756-62. 2004..6-34.1%. Enrolled women had above average risk. Screening sensitivity in both arms was high. A benefit of mammography screening is supported by our modeling of the CNBSS-2 results... - Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combinedEveline A M Heijnsdijk
Department of Public Health, Erasmus MC, Rotterdam, The Netherlands
Cancer Epidemiol Biomarkers Prev 21:1458-68. 2012..Clinical observations suggest important differences in the natural history between breast cancers due to mutations in BRCA1 and BRCA2, potentially requiring different screening guidelines...